C 23 H 22 N 13 Br, triclinic, P1 (no. 2), a = 9.255(6) Å, b = 9.819(6) Å, c = 14.497(9) Å, α = 105.186(7)°, β = 90.030(7)°, γ = 102.228(7)°, V = 1240.3(13) Å 3 , Z = 2, R gt (F) = 0.0434,
CCDC no.: 1587469
The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
A mixture of 2,6-bis(3-(pyrazin-2-yl)-1H-1,2,4-triazol-5-yl) pyridine (0.05 mmol) and [EMI] Br ionic liquid (EMI = 1-elkyl-3-methylimidazolium) (1 g) in 10 mL mixed solvent (CH 3 CN/H 2 O, V/V, 7:3) was placed in a 25 mL Teflon-lined stainless steel vessel, and the vessel was sealed and heated to 160°C for 72 h. After the mixture had been cooled to room temperature, colorless crystals of the title complex were obtained. 
Experimental details
The hydrogen atoms were placed in calculated positions riding on attached atoms with isotropic thermal parameters 1.2 times as those of their carrier atoms. The U iso values of the hydrogen atoms of methyl group was set to 1.5U eq .
Discussion
Metal-organic frameworks (MOFs) have attracted lots of interest because their diverse compositions and framework architectures allow for a high degree of control over their properties [4] . Ionothermal synthesis, a method that uses an ionic liquid as solvent and structure directing agents in the preparation of crystalline solids, offers many advantages over traditional hydrothermal and solvothermal synthesis methods [5] [6] [7] [8] [9] [10] . Syntheses using ILs as solvents have received increasing interest for the preparation of functional materials in the context of crystal engineering. In the past years, the synthetic success using the ionothermal method has opened up a new route for the creation of novel inorganic and metal-organic framework materials. The asymmetric unit contains one neutral 2,6-bis(3-(pyrazin-2-yl)-1H-1,2,4-triazol-5-yl)pyridine, one [EMI] + cation (EMI = 1-elkyl-3-methylimidazolium) and one Br − anion (cf. 
